original ↗
alearningaday.blog·1d
🎓Advanced content
Preview
Report Post

Dr. Peter Attia’s team shared a thoughtful retrospective on a proposed explanation they shared previously.

Two years ago, they shared results from a trial that showed GLP-1 drugs (Ozempic, Wegovy) weren’t just remarkable in combating efficacy and type II diabetes – but that they were also effective in reducing major adverse cardiovascular events (heart attacks, stokes).

Taking a simplistic Occam’s razor inspired approach, they’d suggested that the reduction in cardiovascular risk was likely due to the weight loss involved.

However, additional data released recently showed that the drugs had a separate positive impact on cardiovascular risk because there was no correlation between a patient’s weight loss and thei…

Similar Posts

Loading similar posts...